Emerging viral diseases: Confronting threats with new technologies

Science Translational Medicine

Volumn 6, Issue 253, 2014, Pages

  Marston, Hilary D ^a   Folkers, Gregory K ^a   Morens, David M ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIKUNGUNYA VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ANTIVIRAL THERAPY; BIOLOGICAL WARFARE; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; CLINICAL TRIAL (TOPIC); CORONAVIRUS; CORONAVIRUS INFECTION; CRYOELECTRON MICROSCOPY; DRUG DESIGN; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; HEPATITIS B; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION CONTROL; INFLUENZA; MEDICAL RESEARCH; MERS CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PUBLIC HEALTH; RAPID TEST; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; SARS CORONAVIRUS; SEQUENCE ANALYSIS; SEVERE ACUTE RESPIRATORY SYNDROME; SURVIVAL RATE; VIRAL RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS MUTATION; VIRUS TRANSMISSION; X RAY CRYSTALLOGRAPHY; ZOONOSIS; VIRUS DISEASES;

HUMANS; VIRUS DISEASES;

EID: 84907391790     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009872     Document Type: Review

References (40)

1. Committee on Microbial Threats to Health, Institute of Medicine, Emerging infections: Microbial threats to health in the United States (National Academies Press, Washington, DC, 1992).
2. R. F. Viergever, The mismatch between the health research and development (R&D) that is needed and the R&D that is undertaken: An overview of the problem, the causes, and solutions. Glob. Health Action 6, 22450 (2013).
3. R. Lozano, M. Naghavi, K. Foreman, S. Lim, K. Shibuya, V. Aboyans, J. Abraham, T. Adair, R. Aggarwal, S. Y. Ahn, M. Alvarado, H. R. Anderson, L. M. Anderson, K. G. Andrews, C. Atkinson, L. M. Baddour, S. Barker-Collo, D. H. Bartels, M. L. Bell, E. J. Benjamin et al., Calculated with data from: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012).
4. M. G. Dixon, I. J. Schafer, Centers for Disease Control and Prevention (CDC), Ebola viral disease outbreak - West Africa, 2014. MMWR Morb. Mortal. Wkly. Rep. 63, 548-551 (2014).
5. D. M. Morens, G. K. Folkers, A. S. Fauci, Emerging infections: A perpetual challenge. Lancet Infect. Dis. 8, 710-719 (2008).
6. S. M. Ahmed, A. J. Hall, A. E. Robinson, L. Verhoef, P. Premkumar, U. D. Parashar, M. Koopmans, B. A. Lopman, Global prevalence of norovirus in cases of gastroenteritis: A systematic review and meta-analysis. Lancet Infect. Dis. 14, 725-730 (2014).
7. M. T. Pérez-Gracia, B. Suay, M. L. Mateos-Lindemann, Hepatitis E: An emerging disease. Infect. Genet. Evol. 22, 40-59 (2014).
8. C. M. Byrd, D. W. Grosenbach, D. E. Hruby, Antiviral options for biodefense. Curr. Opin. Virol. 3, 537-541 (2013).
9. F. Renois, D. Talmud, A. Huguenin, L. Moutte, C. Strady, J. Cousson, N. Lévêque, L. Andréoletti, Rapid detection of respiratory tract viral infections and coinfections in patients with influenza-like illnesses by use of reverse transcription-PCR DNA microarray systems. J. Clin. Microbiol. 48, 3836-3842 (2010).
10. H. Feldmann, T. W. Geisbert, Ebola haemorrhagic fever. Lancet 377, 849-862 (2011).
11. T. Rutledge, R. Penciner, K. Popovich, SARS assessment clinic: A rapid response to an infectious outbreak. CJEM 7, 162-167 (2005).
12. J. E. Martin, M. K. Louder, L. A. Holman, I. J. Gordon, M. E. Enama, B. D. Larkin, C. A. Andrews, L. Vogel, R. A. Koup, M. Roederer, R. T. Bailer, P. L. Gomez, M. Nason, J. R. Mascola, G. J. Nabel, B. S. Graham, VRC 301 Study Team, A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 26, 6338-6343 (2008).
13. A. N. Alagaili, T. Briese, N. Mishra, V. Kapoor, S. C. Sameroff, P. D. Burbelo, E. de Wit, V. J. Munster, L. E. Hensley, I. S. Zalmout, A. Kapoor, J. H. Epstein, W. B. Karesh, P. Daszak, O. B. Mohammed, W. I. Lipkin, Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio. 5, e00884-e14 (2014).
14. R. A. Perera, P. Wang, M. R. Gomaa, R. El-Shesheny, A. Kandeil, O. Bagato, L. Y. Siu, M. M. Shehata, A. S. Kayed, Y. Moatasim, M. Li, L. L. Poon, Y. Guan, R. J. Webby, M. A. Ali, J. S. Peiris, G. Kayali, Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill. 18, 20574 (2013).
15. World Health Organization, WHO Statement on the Sixth Meeting of the IHR Emergency Committee Concerning MERSCoV; http://who.int/mediacentre/news/statements/2014/ihr-emergency-committee-merscov/en.
16. H. Feldmann, Ebola - A growing threat? N. Engl. J. Med. 10.1056/NEJMp1405314 (2014).
17. F. Feldmann, H. Feldmann, Ebola: Facing a new transboundary animal disease? Dev. Biol. (Basel) 135, 201-209 (2013).
18. A. K. Zaas, T. Burke, M. Chen, M. McClain, B. Nicholson, T. Veldman, E. L. Tsalik, V. Fowler, E. P. Rivers, R. Otero, S. F. Kingsmore, D. Voora, J. Lucas, A. O. Hero, L. Carin, C. W. Woods, G. S. Ginsburg, A host-based RT-PCR gene expression signature to identify acute respiratory viral infection. Sci. Transl. Med. 5, 203ra126 (2013).
19. M. Kanekiyo, C. J. Wei, H. M. Yassine, P. M. McTamney, J. C. Boyington, J. R. Whittle, S. S. Rao, W. P. Kong, L. Wang, G. J. Nabel, Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102-106 (2013).
20. A. Roldão, M. C. Mellado, L. R. Castilho, M. J. Carrondo, P. M. Alves, Virus-like particles in vaccine development. Expert Rev. Vaccines 9, 1149-1176 (2010).
21. D. M. Morens, A. S. Fauci, Chikungunya at the door - Déjà vu all over again? N. Engl. J. Med. 10.1056/NEJMp1408509 (2014).
22. Centers for Disease Control and Prevention, Chikungunya in the Americas; www.cdc.gov/chikungunya/geo/americas.html.
23. L. J. Chang, K. A. Dowd, F. H. Mendoza, J. G. Saunders, S. Sitar, S. H. Plummer, G. Yamshchikov, U. N. Sarwar, Z. Hu, M. E. Enama, R. T. Bailer, R. A. Koup, R. M. Schwartz, W. Akahata, G. J. Nabel, J. R. Mascola, T. C. Pierson, B. S. Graham, J. E. Ledgerwood, VRC 311 Study Team, Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: A phase 1 dose-escalation trial. Lancet 10.1016/S0140-6736(14)61185-5 (2014)
24. P. D. Kwong, J. R. Mascola, G. J. Nabel, Broadly neutralizing antibodies and the search for an HIV-1 vaccine: The end of the beginning. Nat. Rev. Immunol. 13, 693-701 (2013).
25. J. Cohen, HIV surface proteins finally caught going au naturel. Science 342, 546-547 (2013).
26. M. Shingai, Y. Nishimura, F. Klein, H. Mouquet, O. K. Donau, R. Plishka, A. Buckler-White, M. Seaman, M. Piatak, Jr, J. D. Lifson, D. S. Dimitrov, M. C. Nussenzweig, M. A. Martin, Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277-280 (2013).
27. N. E. Kohl, E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, I. S. Sigal, Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 85, 4686-4690 (1988).
28. A. Wlodawer, Rational approach to AIDS drug design through structural biology. Annu. Rev. Med. 53, 595-614 (2002).
29. D. J. Hazuda, J. C. Hastings, A. L. Wolfe, E. A. Emini, A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Res. 22, 1121-1122 (1994).
30. Q. L. Choo, G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, M. Houghton, Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989).
31. Y. Chang, E. Cesarman, M. S. Pessin, F. Lee, J. Culpepper, D. M. Knowles, P. S. Moore, Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266, 1865-1869 (1994).
32. B. G. van den Hoogen, J. C. de Jong, J. Groen, T. Kuiken, R. de Groot, R. A. Fouchier, A. D. Osterhaus, A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat. Med. 7, 719-724 (2001).
33. World Health Organization, Hepatitis C; www.who.int/mediacentre/factsheets/fs164/en.
34. J. R. Kramer, F. Kanwal, P. Richardson, M. Mei, H. B. El-Serag, Gaps in the achievement of eff ectiveness of HCV treatment in national VA practice. J. Hepatol. 56, 320-325 (2012).
35. R. T. Chung, T. F. Baumert, Curing chronic hepatitis C - The arc of a medical triumph. N. Engl. J. Med. 370, 1576-1578 (2014).
36. Y. Furuta, B. B. Gowen, K. Takahashi, K. Shiraki, D. F. Smee, D. L. Barnard, Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 100, 446-454 (2013).
37. T. H. Rider, C. E. Zook, T. L. Boettcher, S. T. Wick, J. S. Pancoast, B. D. Zusman, Broad-spectrum antiviral therapeutics. PLOS One 6, e22572 (2011).
38. S. T. Perry, M. D. Buck, E. M. Plummer, R. A. Penmasta, H. Batra, E. J. Stavale, K. L. Warfield, R. A. Dwek, T. D. Butters, D. S. Alonzi, S. M. Lada, K. King, B. Klose, U. Ramstedt, S. Shresta, An iminosugar with potent inhibition of dengue virus infection in vivo. Antiviral Res. 98, 35-43 (2013).
39. T. K. Warren, J. Wells, R. G. Panchal, K. S. Stuthman, N. L. Garza, S. A. Van Tongeren, L. Dong, C. J. Retterer, B. P. Eaton, G. Pegoraro, S. Honnold, S. Bantia, P. Kotian, X. Chen, B. R. Taubenheim, L. S. Welch, D. M. Minning, Y. S. Babu, W. P. Sheridan, S. Bavari, Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508, 402-405 (2014).
40. E. P. Thi, C. E. Mire, R. Ursic-Bedoya, J. B. Geisbert, A. C. H Lee, K. N. Agans, M. Robbins, D. J. Deer, K. A. Fenton, I. MacLachlan, T. W. Geisbert, Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA. Sci. Transl. Med. 6, 250ra116 (2014).